Maia Biotechnology Inc. has announced changes to its management team with the appointment of two prominent oncologists, Claudia Fulgenzi, MD, and David J. Pinato, MD, PhD, to its Scientific Advisory Board. Both experts will provide guidance on the design and protocols for Maia's upcoming clinical trial in hepatocellular carcinoma, focusing on the company's lead candidate ateganosine (THIO) combined with a checkpoint inhibitor. This development is part of Maia's ongoing efforts in targeted immunotherapies for cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.